Metformin
Metformin has been studied in 2,400 papers since 1984: 220 trials and 503 observational studies in people, 599 in animals, 206 in cells, 768 reviews; 962 in the past year. It is an approved medicine. The newest paper, Nov 16, 2026: “Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 10 mg in Korean Adults With Type 2 Diabetes:…”.
InterventionBiguanidesApproved 1995
2,400 papers study it382 more mention it3,113 findingsUpdated
Research on it is growing 26% faster than aging research as a whole: 111 papers in the latest year counted
Part of Bryan Johnson's Blueprint and David Sinclair's daily regimen in Lifespan
209 new papers in 30 daysSee all 2,747 papers on metformin
At a glance
Independent labs found the same change in cells, worms or flies, mice and people. 573 independent labs in 69 countries; 1,170 trials, 140 about aging, 502 with no results posted.
“Randomization to metformin was associated with higher odds of progression to high ABI (adjusted OR=1.35, 95% CI 1.04-1.77, p=0.027) relative to placebo”
263 of its findings point the other way.
- 573 independent labs in 69 countries
- 263 findings against
- 1,170 trials, 140 about aging, 502 with no results posted
- Funders: National Institutes of Health and others
- 181 of 2,682 findings with company ties
- 38 of 1,170 trials sponsored by its developers
- Human trial219
- Humans496
- Animals535
- Model organisms53
- Cells198
- In silico43
Studies in people
See all 146 studies of metformin in people146 studies gave metformin to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on body weight | Randomized trial8 weeks | 38 peopleWomen25–35 yearsAdjunctive to a very-low-carbohydrate, low-calorie, high-protein diet in overweight or obese women with PMOS; baseline-adjusted comparison | Nutrition journal, Nov 12, 2026 |
no change: Has no effect on total prolactin45.85 ± 5.06 to 45.00 ± 5.04 ng/mL | Trial6 months | 120 peopleWomenPCOS; before-and-after comparison without an untreated comparator | Pathophysiology : the official journal of the International Society for Pathophysiology, Nov 10, 2026 |
up: Improves composite glycemic outcomeWin ratio 1.46 (95% CI 1.13–1.89); net treatment benefit 13.7 percentage points (95% CI 4.3–22.8) | Randomized trialFollow-up through 12 weeks postpartum | 526 peopleMean 34.4 years (SD 4.8)Gestational diabetes; early initiation plus usual care versus placebo plus usual care | JAMA network open, Nov 3, 2026 |
down: Decreases body weight−2.0 kg from baseline down: Decreases HbA1c | Randomized trial6 months | 217 people30–70 yearsMidlife adults; Older adults; Prediabetes and body mass index ≥23 kg/m2; change from baseline | Diabetes & metabolism journal, Nov 1, 2026 |
up: Improves systemic insulin sensitivity down: Protects against regional brain glucose uptake decline | Randomized trial40 weeks | 40 peopleolder adultsOlder adults; insulin resistance | The Journal of clinical investigation, Oct 27, 2026 |
What did mouse lifespan tests of metformin find?
NIA ITPThe NIA Interventions Testing Program ran 1 arm in 2011; the change in median lifespan ran from 0% to +7%.
What did other lifespan studies of metformin find?
DrugAgeDrugAge records 52 results from 15 papers: 21 in D. melanogaster, 20 in C. elegans, 7 in mice and 3 other species. Average lifespan is the mean or the median, as each paper reports it.
- D. melanogasterwDah, females, 0.5 mM+17.2% average
- C. elegansN2, 6.25 mM+1.7% averagenot significant
- MiceC57BL/6, females, 100 ppm/day bodyweight oral gavage, from 20 months−2% average
- A. domesticusmales, 1.78x10^3 g metformin/g diet+39% average
- N. guentherimales, 2 mg/g food+34.7% average+12.2% maximum
- RatsFischer 344, 300 mg/kg/day+2.3% averagenot significant+2.1% maximum
What did studies of metformin find?
443Studies of metformin measured 443 outcomes; the most studied are inflammation (22 studies), cellular senescence (16) and AMPK signaling (15).
Inflammation
downin reviews8downin human cells4downin rats4downin mice3+3
22 studies
Inflammation
downin reviews8downin human cells4downin rats4downin mice3+3
Metformin decreases inflammation in the L4-6 SDH of DM rats.
“metformin intervention reduced the activation levels of microglia and astrocytes in the L4-6 SDH of DM rats”
Animalsin the L4-6 SDH of DM ratsspinal dorsal horn
Mechanism by which metformin alleviates neuralgia in the spinal cord of diabetic rats
Neuroscience
Metformin decreases inflammation in human cells (cells from healthy donors).
“it exerted both anti-inflammatory and anti-autophagic effects on these cells, as evidenced by downregulation of IL-6 and MAPLC3 expression”
Cellscells from healthy donorsnormal colonocytes
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
Metformin decreases inflammation.
“the reduction of oxidative stress and inflammatory mediators”
Reviewarticular cartilage
Frontiers in immunology
Metformin decreases inflammation in ICV-STZ-treated rats.
“suppressed TNF-α, IL-1β, and iNOS expression”
Animalsin ICV-STZ-treated ratshippocampus2 g/L12 weeksmales
European journal of pharmacology
Metformin decreases inflammation (as reported in studies cited by the review).
“metformin suppresses neuroinflammation by inhibiting the NF-κB signaling pathway and the NLRP3 inflammasome”
Reviewas reported in studies cited by the review
Metformin in Neurodegenerative Diseases: Mechanisms and Therapeutic Implications
Current neuropharmacology
Metformin decreases inflammation in rats (LPS-induced).
“attenuating LPS-induced oxidative stress and inflammatory damage in placental tissue and trophoblast cells.”
AnimalsLPS-inducedplacentafemales
European journal of pharmacology
Metformin decreases inflammation.
“Metabolic modulators such as metformin and rapamycin attenuate inflammatory signaling”
Review
Inflammaging: Experimental Insights and Translational Advances
European journal of immunology
Metformin decreases inflammation.
“exhibiting several properties, including antioxidant, anti-inflammatory, and anti-apoptotic effects across various tissues”
Reviewvarious tissues
Mechanistic Insights into metformin's neuroprotective effects against drug-induced neurotoxicity
Metabolic brain disease
Metformin decreases inflammation (preliminary findings, context-dependent).
“metformin may modulate microbial fitness, attenuate excessive inflammation, and influence bone remodeling”
Reviewpreliminary findings, context-dependent
Antibiotics (Basel, Switzerland)
Metformin decreases inflammation in human cells under Ang II challenge (near-baseline levels).
“Metformin markedly suppressed these responses, reducing cytokine expression toward near-baseline levels”
Cellsunder Ang II challengeheart
Iranian journal of pharmaceutical research : IJPR
All 22Fewer
Cellular senescence
downin human cells5downin cells4downin mice3downin C. porcellus1+3
16 studies
Cellular senescence
downin human cells5downin cells4downin mice3downin C. porcellus1+3
Metformin decreases cellular senescence in human cells (late-passage and D-galactose-treated THESCs).
“Metformin significantly restored cell proliferation, reduced senescence markers (P16, P21), and alleviated mitochondrial dysfunction and oxidative stress in late-passage and D-galactose-treated THESCs.”
Cellslate-passage and D-galactose-treated THESCshuman endometrial stromal cells
European journal of pharmacology
Metformin decreases cellular senescence in human cells (hyperosmotic stress; metformin pretreatment).
“In vitro, metformin pretreatment significantly attenuated hyperosmolarity-induced cell death, ROS accumulation, and the expression of senescence and inflammatory markers.”
Cellshyperosmotic stress; metformin pretreatmenthuman corneal epithelial cells
Experimental eye research
Metformin decreases cellular senescence in human cells (hydrogen peroxide- and high-glucose/high-lipid-induced senescence).
“metformin treatment effectively attenuated hydrogen peroxide- and high-glucose/high-lipid-induced fibroblast senescence in vitro”
Cellshydrogen peroxide- and high-glucose/high-lipid-induced senescencefibroblast
Artery disease and diabetic foot ulcers share gene-activity patterns
Research SquarePreprint
Metformin decreases cellular senescence in human cells (ACS patient-derived cells).
“Treatment with metformin or SRT1720 partially reversed the senescent and dysfunctional phenotype, improving metabolic and functional readouts.”
CellsACS patient-derived cellsiPSC-derived endothelial cell
ESC Congress 2026 abstract
Metformin decreases cellular senescence in mice (combined with PLA/nHA scaffold in aged femoral defects).
“In aged femoral defects, PLA/nHA/metformin reduced local senescence and accelerated new bone formation”
Animalscombined with PLA/nHA scaffold in aged femoral defectsfemur
Scaffold and metformin sped new bone formation in aged mice
Nano Research
Metformin decreases cellular senescence in human cells (tert-butyl hydroperoxide-exposed NP-MSCs).
“In NP-MSCs exposed to tert-butyl hydroperoxide, metformin increased AMPK phosphorylation and SIRT1 expression, enhanced UPRmt signaling, and reduced apoptosis and senescence.”
Cellstert-butyl hydroperoxide-exposed NP-MSCsnucleus pulposus
Free radical biology & medicine
Metformin decreases cellular senescence in cells (TGF-β-induced).
“Metformin significantly attenuated transforming growth factor-β (TGF-β)-induced cardiac fibroblast activation and the associated senescence-like phenotype.”
CellsTGF-β-induced
Cells
Metformin decreases cellular senescence in pigs (Ang II-induced, measured as P21 expression).
“reduced Ang II-induced expression of matrix remodelling (MMP1, MMP2) and senescence (P21) markers”
AnimalsAng II-induced, measured as P21 expressioncoronary artery
British journal of pharmacology
Metformin decreases cellular senescence in D-galactose-induced CM aging model.
“MET significantly attenuated D-galactose-induced senescence in CM tissue and primary CSMCs”
Animalsin D-galactose-induced CM aging model
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Metformin decreases cellular senescence in H2O2-treated cells.
“Metformin pretreatment significantly reduced H2O2-induced senescent cell number.”
Cellsin H2O2-treated cellsevery 72 h
Cell and Tissue Biology
All 16Fewer
AMPK signaling
upin reviews8upin rats3upin human cells1upin humans1+2
15 studies
AMPK signaling
upin reviews8upin rats3upin human cells1upin humans1+2
Metformin activates AMPK signaling in the L4-6 SDH of DM rats.
“Metformin intervention significantly elevated the levels of phosphorylated-AMPK (p-AMPK, the activated form of AMPK) in the L4-6 spinal dorsal horn (SDH) of DM rats.”
Animalsin the L4-6 SDH of DM ratsspinal dorsal horn
Mechanism by which metformin alleviates neuralgia in the spinal cord of diabetic rats
Neuroscience
Metformin activates AMPK signaling.
“For instance, metformin activates AMPK, inhibiting mTOR and promoting apoptosis”
Review
Type 2 diabetes medications and their implications for cancer treatment: A comprehensive review
Molecular aspects of medicine
Metformin activates AMPK signaling (Narrative synthesis of metformin, SGLT2 inhibitors, and intermittent fasting).
“We delineate molecular convergence on adenosine monophosphate kinase (AMPK) activation”
ReviewNarrative synthesis of metformin, SGLT2 inhibitors, and intermittent fasting
Current issues in molecular biology
Metformin activates AMPK signaling in rat cells (diabetic erectile dysfunction model).
“Mechanistically, DMBG activated AMPK and inhibited mTOR phosphorylation in PCECs, increasing eNOS.”
Cellsdiabetic erectile dysfunction modelprimary cavernosal endothelial cells
Journal of reproductive immunology
Metformin activates AMPK signaling.
“It acts by activating the AMPK, which leads to a cascade of downstream events such as the inhibition of mTOR, increased mitochondrial biogenesis, and autophagy”
Review
Metformin at the convergence of aging and longevity
Aging
Metformin activates AMPK signaling.
“metformin may confer cardiovascular benefits through activation of AMP-activated protein kinase”
Review
Metformin: A Promising Candidate for Slowing the Progression of Cardiovascular Aging
Aging and disease
Metformin activates AMPK signaling in LPS-induced preeclampsia model.
“Both MEL and MET individually activated the AMPK/SIRT3 signaling pathway, thereby enhancing mitochondrial function and placental energy homeostasis”
Animalsin LPS-induced preeclampsia modelplacentafemales
European journal of pharmacology
Metformin activates AMPK signaling.
“achieves mTOR suppression, AMPK activation, and downstream anti-proliferative effects through an overlapping molecular pathway”
Review
Mechanistic Review — Metformin as a Caloric Restriction Mimetic in Helminth-Endemic Populations
Zenodo (CERN European Organization for Nuclear Research)Preprint
Metformin activates AMPK signaling in mice.
“metformin activated AMP-activated protein kinase (AMPK)”
Animalslung
B77-21 Senomorphic Effects of Metformin Promotes Resolution of Age-Associated Lung Fibrosis
American Journal of Respiratory and Critical Care Medicine
Metformin activates AMPK signaling.
“Metformin activates AMPK, improving mitochondrial function and reducing oxidative stress in neurons.”
Reviewneuron
Metformin for Diabetes-Associated Cognitive Decline
Zenodo (CERN European Organization for Nuclear Research)Preprint
All 15Fewer
Oxidative stress and ROS signaling
downin reviews5downin human cells4downin cells1upin human cells1+3
13 studies
Oxidative stress and ROS signaling
downin reviews5downin human cells4downin cells1upin human cells1+3
Metformin decreases oxidative stress and ROS signaling in human cells (late-passage and D-galactose-treated THESCs).
“Metformin significantly restored cell proliferation, reduced senescence markers (P16, P21), and alleviated mitochondrial dysfunction and oxidative stress in late-passage and D-galactose-treated THESCs.”
Cellslate-passage and D-galactose-treated THESCshuman endometrial stromal cells
European journal of pharmacology
Metformin decreases oxidative stress and ROS signaling in rats (cisplatin-induced acute kidney injury).
“Treatment with metformin or intermittent fasting significantly improved renal function tests, reduced oxidative stress”
Animalscisplatin-induced acute kidney injurykidney200 mg/kg12 daysmales
Scientific reports
Metformin increases oxidative stress and ROS signaling in human cells.
“increased mitochondrial mass and mitochondrial ROS (mtROS) production.”
CellsPBMCs20 mM24 hours
Research SquarePreprint
Metformin decreases oxidative stress and ROS signaling in humans (obesity).
“These approaches improve glycemic control, reduce inflammation and oxidative stress, enhance endothelial function, and contribute to cardiovascular protection.”
Reviewobesity
Endothelial Dysfunction and Obesity: New Diagnostic and Therapeutic Strategies
International journal of molecular sciences
Metformin decreases oxidative stress and ROS signaling (preclinical work).
“Preclinical work suggests these pathways enhance mitochondrial biogenesis, reduce oxidative stress”
Reviewpreclinical work
Metformin: A Promising Candidate for Slowing the Progression of Cardiovascular Aging
Aging and disease
Metformin decreases oxidative stress and ROS signaling.
“exhibiting several properties, including antioxidant, anti-inflammatory, and anti-apoptotic effects across various tissues”
Reviewvarious tissues
Mechanistic Insights into metformin's neuroprotective effects against drug-induced neurotoxicity
Metabolic brain disease
Metformin decreases oxidative stress and ROS signaling in H2O2-induced senescent HUVECs.
“metformin regulated mitochondrial dynamics, restored mitochondrial membrane potential, and attenuated intracellular oxidative stress”
Cellsin H2O2-induced senescent HUVECs
International journal of molecular sciences
Metformin decreases oxidative stress and ROS signaling in human cells under Ang II challenge (120.0 ± 2.0% vs 187.7 ± 2.5% of control).
“lowering ROS to 120.0 ± 2.0%, decreasing the BAX/BCL-2 ratio from 2.98 to 1.19, and reducing cleaved caspase-3 and cleaved PARP to 120% and 112% of control, respectively.”
Cellsunder Ang II challengeheart
Iranian journal of pharmaceutical research : IJPR
Metformin decreases oxidative stress and ROS signaling in H2O2-treated cells.
“H2O2–induced increase in levels of p53, p21WAF1, IL-6, CXCL1, and CCL2 mRNA and ROS was significantly inhibited by metformin.”
Cellsin H2O2-treated cellsevery 72 h
Cell and Tissue Biology
Metformin decreases oxidative stress and ROS signaling.
“Metformin activates AMPK, improving mitochondrial function and reducing oxidative stress in neurons.”
Reviewneuron
Metformin for Diabetes-Associated Cognitive Decline
Zenodo (CERN European Organization for Nuclear Research)Preprint
All 14Fewer
Autophagy
upin cells3upin rats2upin C. porcellus cells1downin human cells1+3
10 studies
Autophagy
upin cells3upin rats2upin C. porcellus cells1downin human cells1+3
Metformin activates autophagy in rats (MCAO/R rats).
“Met activated the AMPK/mTOR pathway and promoted autophagic flux in hippocampal tissue”
AnimalsMCAO/R ratshippocampus
Frontiers in pharmacology
Metformin inhibits autophagy in human cells (cells from healthy donors).
“it exerted both anti-inflammatory and anti-autophagic effects on these cells, as evidenced by downregulation of IL-6 and MAPLC3 expression”
Cellscells from healthy donorsnormal colonocytes
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
Metformin improves autophagy in cells (MMAE-ADC-associated stress).
“Metformin improved lysosomal and autophagy-associated readouts”
CellsMMAE-ADC-associated stressmacrophage
PLA2G4A-Associated macrophage lysosomal stress contributes to MMAE-ADC-induced peripheral neuropathy
Journal of neuroinflammation
Metformin activates autophagy in rats (streptozotocin-induced diabetic erectile dysfunction).
“It downregulated elevated serum VEGF-A and upregulated impaired penile autophagy markers (LC3-II, BECLIN1, ATG5).”
Animalsstreptozotocin-induced diabetic erectile dysfunctionpenis30 days
Journal of reproductive immunology
Metformin activates autophagy.
“the activation of AMPK/SIRT1-mediated autophagy”
Reviewarticular cartilage
Frontiers in immunology
Metformin increases autophagy in human cells (chromosome 21 trisomy).
“including attenuation of mTOR-associated signaling, enhancement of autophagic flux and normalization of mitophagy-related protein levels”
Cellschromosome 21 trisomyfibroblast
Cellular and molecular life sciences : CMLS
Metformin activates autophagy in senescent macrophages in the inflammaging microenvironment.
“The released metformin restores intracellular homeostasis by enhancing autophagy”
Cellsin senescent macrophages in the inflammaging microenvironmentreleased from implant
Recasting Inflammaging into Regeneration
Rare Metals
Metformin increases autophagy in senescent macrophages (about 1-fold higher autophagosome fluorescence).
“0.1 mM metformin restored S‐MΦ homeostasis by enhancing autophagy (about 1‐fold higher autophagosome fluorescence)”
Cellsin senescent macrophages0.1 mM
Rare Metals
Metformin activates autophagy in rat cells (compared with the control group).
“autophagy (Beclin-1↑, LC3-II/-I ratio↑, P62↓) and an inhibition of autophagy (LC3↓) in testicular organoids after treatment with Met and HCQ, respectively”
Cellscompared with the control grouptesticular organoid5 μM7 days
Advanced pharmaceutical bulletin
Metformin increases autophagy in aged CSMCs.
“In addition, MET restored autophagic activity in aged CSMCs and helped maintain intracellular and mitochondrial homeostasis.”
Cellsin aged CSMCs
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Body weight
downin humans6no changein humans1upin rats1
8 studies
Body weight
downin humans6no changein humans1upin rats1
Metformin showed no clear effect on body weight in humans.
“no significant between-group differences in any outcome after adjustment.”
Human trialAdjunctive to a very-low-carbohydrate, low-calorie, high-protein diet in overweight or obese women with PMOS; baseline-adjusted comparison8 weeksfemalesn = 38
Nutrition journal
Metformin decreases body weight in humans (Prediabetes and body mass index ≥23 kg/m2; change from baseline) (−2.0 kg from baseline).
“all groups showed significant weight reduction (−0.7 kg STM, −2.3 kg LSM, −2.0 kg MET; P<0.001).”
Human trialPrediabetes and body mass index ≥23 kg/m2; change from baseline6 monthsn = 217
Diabetes & metabolism journal
Metformin decreases body weight in humans (-5.7±5.2 vs. -2.3±5.4 kg).
“Metformin led to more weight loss than placebo (-5.7±5.2 vs . -2.3±5.4 kg, p=0.0002)”
Human trialtwo yearsn = 145
A Randomized Clinical Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance
medRxiv : the preprint server for health sciencesPreprint
Metformin decreases body weight in humans (net weight loss, p<0.005).
“MET led to a net weight loss (p<0.005)”
Human trial2 yearsn = 15
ADA Scientific Sessions 2026 abstract
Metformin is linked with lower body weight in humans (add-on therapy) (36.9% (79/214) lost ≥5% of baseline weight).
“79/214 (36.9%) with add-on metformin”
Humansadd-on therapy12 monthsn = 214
Acta psychiatrica Scandinavica
Metformin decreases body weight in humans (MD -3.86 kg (95% CI -5.02 to -2.70)).
“metformin (MD, -3.86 kg; 95% CI, -5.02 to -2.70; k = 16; moderate certainty)”
Reviewin antipsychotic-treated patients with schizophrenia spectrum disorders, versus placebo or standard care
JAMA psychiatry
Metformin decreases body weight in PMOS.
“Metformin is associated with modest reductions in body weight and improves metabolic and anthropometric outcomes.”
Reviewin PMOS
Pharmacological treatment of polyendocrine metabolic ovarian syndrome in adults
Drug and therapeutics bulletin
Metformin increases body weight in high-fat diet and STZ-induced T2DM rats.
“All treated groups showed significantly higher body weights than DC, indicating protection against STZ-induced weight loss.”
Animalsin high-fat diet and STZ-induced T2DM rats28 daysmalesn = 30
Antidiabetic effects of Gymnema sylvestre and metformin co-therapy in a type 2 diabetic rat model
World journal of experimental medicine
Cell viability
upin human cells3no changein human cells2downin human cells1downin rat cells1+1+106%
7 studies
Cell viability
upin human cells3no changein human cells2downin human cells1downin rat cells1+1+106%
Metformin showed no clear effect on cell viability in human cells (cells from healthy donors).
“Metformin did not affect the viability of normal colonocytes.”
Cellscells from healthy donorsnormal colonocytes
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
Metformin showed no clear effect on cell viability in human cells (cisplatin exposure).
“While Met did not significantly reduce SA-β-gal activity or restore cell viability”
Cellscisplatin exposureinduced pluripotent stem cell-derived motor neurons
Toxicology mechanisms and methods
Metformin increases cell viability in human cells (106.30%).
“The 100 μM dose significantly maximized cell viability (106.30%) and clonogenicity”
Cells100 μM
Research SquarePreprint
Metformin improves cell viability in human cells under Ang II challenge (89.7 ± 1.0% with 1.0 mM vs 53.0-64.9% with Ang II).
“Metformin attenuated this injury in a concentration-dependent manner, restoring viability to 81.7 ± 1.0% with 0.5 mM and 89.7 ± 1.0% with 1.0 mM”
Cellsunder Ang II challengeheart0.5 or 1.0 mM
Iranian journal of pharmaceutical research : IJPR
Metformin decreases cell viability in human cells after 48 h (IC50 2.28 mM).
“Metformin induced dose- and time-dependent cytotoxicity in all cell lines, with the lowest IC50 values in HeLa and A549 cells after 48 h (2.28 and 3.30 mM; p < 0.05).”
Cellsafter 48 hcervical carcinoma cell line48 h
Preprints.orgPreprint
Metformin decreases cell viability in rat cells (at 100 mM) (complete loss).
“a dose of 100 mM was cytotoxic to osteoblasts and resulted in a complete loss of their viability.”
Cellsat 100 mM100 mM
Physiological research
Metformin improves cell viability in rat cells (at concentrations up to 1 mM).
“MET at concentrations up to 1 mM can promote osteoblast viability, osteogenic differentiation, angiogenic signaling, and reduce osteoclastogenesis.”
Cellsat concentrations up to 1 mM
Physiological research
Metformin increases cell viability in human cells (MPP+-treated cells; metformin pretreatment).
“The results showed that pretreatment with metformin increased the viability of MPP+-treated SH-SY5Y cells.”
CellsMPP+-treated cells; metformin pretreatmentdifferentiated SH-SY5Y cells
EXCLI journal
Apoptosis
upin human cells1downin mice1downin rat cells1downin rats1+1
5 studies
Apoptosis
upin human cells1downin mice1downin rat cells1downin rats1+1
Metformin decreases apoptosis in mice (benzalkonium chloride-induced dry eye disease).
“In vivo, systemic administration of metformin preserved corneal epithelial thickness, decreased apoptosis, and reduced senescence markers in DED mice.”
Animalsbenzalkonium chloride-induced dry eye diseasecorneal epithelium
Experimental eye research
Metformin decreases apoptosis in rat cells (cells isolated from metformin-treated diabetic erectile dysfunction rats).
“PCECs from DMBG-treated rats exhibited rescued viability, angiogenesis, migration, and reduced apoptosis, alongside reactivated autophagy.”
Cellscells isolated from metformin-treated diabetic erectile dysfunction ratsprimary cavernosal endothelial cells
Journal of reproductive immunology
Metformin decreases apoptosis.
“exhibiting several properties, including antioxidant, anti-inflammatory, and anti-apoptotic effects across various tissues”
Reviewvarious tissues
Mechanistic Insights into metformin's neuroprotective effects against drug-induced neurotoxicity
Metabolic brain disease
Metformin induces apoptosis in human cells.
“Increased apoptosis and elevated p53 expression suggest activation of tumor-suppressive pathways.”
Cellscervical carcinoma cell line
Preprints.orgPreprint
Metformin decreases apoptosis in SUI rats after double vaginal dilation.
“TUNEL assay showed that metformin treatment reduced apoptotic cells in the EUS from SUI rats.”
Animalsin SUI rats after double vaginal dilationexternal urethral sphincter200 mg/kg/day
Animal models and experimental medicine
Vitamin B12
downin humans5
5 studies
Vitamin B12
downin humans5
Metformin decreases vitamin B12 in humans.
“Metformin assignment was associated with lower B12 levels over follow-up compared with placebo (β= -0.026, SE= 0.011, p= .0017).”
Human trialover follow-up
ADA Scientific Sessions 2026 abstract
Metformin is linked with lower vitamin B12 in humans (mean 646.4 vs 707.4 pg/mL).
“Metformin users also had lower vitamin B12 levels (mean, 646.4 vs 707.4 pg/mL)”
Humans
Journal of hand surgery global online
Metformin is linked with lower vitamin B12 in humans (type 2 diabetes) (569.3 vs. 825.3 pg/mL).
“Metformin users had lower serum B12 (569.3 vs. 825.3 pg/mL; p = 0.026)”
Humanstype 2 diabetesn = 587
Diabetes, obesity & metabolism
Metformin is linked with lower vitamin B12 in humans (T2DM patients on metformin therapy) (389.4 pg/mL (<1 year) to 196.8 pg/mL (>5 years) (p<0.001)).
“Mean serum B12 declined significantly with increasing duration: 389.4 pg/mL (<1 year) to 196.8 pg/mL (>5 years) (p<0.001).”
HumansT2DM patients on metformin therapyn = 312
International Journal of Drug Delivery Technology
Metformin is linked with lower vitamin B12 in type 2 diabetes mellitus (206.66 ± 59.09 pg/mL vs 301.44 ± 72.28 pg/mL).
“The mean serum vitamin B12 level in metformin users was significantly lower than in controls (206.66 ± 59.09 pg/mL vs 301.44 ± 72.28 pg/mL, p < 0.001).”
Humansin type 2 diabetes mellitus1238.89 ± 586.50 mg/day5.22 ± 3.77 years
To Determine Vitamin B12 Deficiency in Type 2 Diabetes Mellitus Patients on Metformin Therapy
The Journal of the Association of Physicians of India
Mortality
downin humans3upin humans1downin mice1OR 0.84
5 studies
Mortality
downin humans3upin humans1downin mice1OR 0.84
Metformin is linked with lower mortality in humans (aHR 0.75 (95% CI 0.73-0.77)).
“Metformin users had lower observed all-cause mortality than DPP-4 inhibitor users (aHR, 0.75; 95% CI, 0.73-0.77)”
Humansversus DPP-4 inhibitors, observed in a retrospective cohort with residual confounding possible
Diabetology & metabolic syndrome
Metformin is linked with higher mortality in humans (glioblastoma) (HR = 1.22; 95% CI: 1.10-1.34).
“linked to increased mortality between 3-9 months (HR = 1.22; 95% CI: 1.10-1.34)”
Humansglioblastoma3-9 monthsn = 16,069
Metformin exposure after glioblastoma diagnosis and mortality: A large population-based study
Neuro-oncology advances
Metformin decreases mortality in type 2 diabetes (OR 0.84, 0.74-0.95).
“metformin lowered all-cause mortality risk by 16% (OR 0.84, 0.74-0.95)”
Reviewin type 2 diabetesn = 939,064
Therapeutic advances in endocrinology and metabolism
Metformin decreases mortality in diabetic and non-diabetic populations.
“It has been shown that the anti-diabetic metformin reduces mortality and the incidence of several age-related diseases”
Reviewin diabetic and non-diabetic populations
Molecular and cellular endocrinology
Metformin decreases mortality in mice (pentylenetetrazol-induced seizures) (P < 0.001).
“The mortality rate, the length of generalized tonic-clonic seizures, the frequency of seizures, and the seizure scores (P < 0.001) were all substantially reduced by the MET.”
Animalspentylenetetrazol-induced seizures200, 250, and 300 mg/kg7 days
Journal of advanced pharmaceutical technology & research
Fasting blood glucose
downin humans2no changein rats1downin rats1
4 studies
Fasting blood glucose
downin humans2no changein rats1downin rats1
Metformin decreases fasting blood glucose in humans among women carrying a male foetus (mean glucose 4.88 mmol/L vs. 5.01 mmol/L).
“Among women carrying a male foetus, metformin reduced the primary composite outcome (55% vs. 68%, p = 0.024), insulin use (38% vs. 53%, p = 0.014) and fasting glucose at 32 and 38 weeks (mean glucose 4.88 mmol/L vs. 5.01 mmol/L, p = 0.021 and 4.49 mmol/L vs. 4.69 mmol/L, p = 0.002), respectively.”
Human trialamong women carrying a male foetusn = 289
BMC medicine
Metformin decreases fasting blood glucose in male pregnancies complicated by GDM (4.88 vs. 5.01 mmol/L, p = 0.014 at 32 weeks; 4.49 vs. 4.69 mmol/L, p = 0.002 at 38 weeks).
“metformin exposure in male pregnancies was associated with lower fasting glucose at 32 (4.88 vs. 5.01 mmol/L, p = 0.014) and 38 weeks (4.49 vs. 4.69 mmol/L, p = 0.002)”
Human trialin male pregnancies complicated by GDMmales
BMC medicine
Metformin showed no clear effect on fasting blood glucose in rats (streptozotocin-induced diabetes; evaluated at week 8).
“final fasting blood glucose did not differ significantly between T and D4.”
Animalsstreptozotocin-induced diabetes; evaluated at week 8100 mg/kg/daymales
Journal of clinical medicine
Metformin decreases fasting blood glucose in humans (pregnant women with gestational diabetes mellitus; compared with insulin) (SMD -0.29 (95% CI -0.55 to -0.03)).
“Metformin achieved glycemic control comparable to insulin, with a pooled SMD for fasting blood glucose (FBG) of -0.29 (95% CI: -0.55 to -0.03; P = 0.03).”
Reviewpregnant women with gestational diabetes mellitus; compared with insulinfemales
Journal of family medicine and primary care
Metformin decreases fasting blood glucose in high-fat diet and STZ-induced T2DM rats.
“Metformin produced the greatest reductions in FBG, cholesterol, creatinine, and glycated hemoglobin.”
Animalsin high-fat diet and STZ-induced T2DM rats28 daysmalesn = 30
Antidiabetic effects of Gymnema sylvestre and metformin co-therapy in a type 2 diabetic rat model
World journal of experimental medicine
HbA1c
downin humans4
4 studies
HbA1c
downin humans4
Metformin decreases HbA1c in humans (Prediabetes and body mass index ≥23 kg/m2).
“a significant reduction in HbA1c was observed only in the MET group.”
Human trialPrediabetes and body mass index ≥23 kg/m26 monthsn = 217
Diabetes & metabolism journal
Metformin is linked with lower HbA1c in humans (Newly diagnosed type 2 diabetes mellitus; no prior oral hypoglycemic medication) (6.85% versus 7.29% at baseline).
“The HbA1c level significantly reduced after the 12-week treatment period (6.85% vs 7.29% at baseline, P = .001).”
HumansNewly diagnosed type 2 diabetes mellitus; no prior oral hypoglycemic medication12 weeksn = 68
Medicine
Metformin is linked with lower HbA1c in humans (newly diagnosed type 2 diabetes) (median 7.8 to 7.2; p = 0.001).
“The HbA1c level decreased from 7.8 (6.9-8.9) to 7.2 (6.5-8.1) (p = 0.001).”
Humansnewly diagnosed type 2 diabetessix monthsn = 52
Cureus
Metformin decreases HbA1c in humans (MD -0.070%).
“At 12 months, metformin significantly reduced waist circumference (MD -1.12 cm; p = 0.014), HbA1c (MD -0.070%; p = 0.029)”
ReviewAdded to androgen-deprivation therapy in prostate cancer, versus androgen-deprivation therapy alone12 months
Prostate cancer and prostatic diseases
IL-6
downin humans2downin human cells1
3 studies
IL-6
downin humans2downin human cells1
Metformin decreases IL-6 in humans (Peri-implantitis; adjunctive to mechanical debridement versus mechanical debridement alone) (8.13 pg/mL vs. 19.23 pg/mL).
“IL-6 levels (8.13 pg/mL vs. 19.23 pg/mL, P < 0.001) compared with the control.”
Human trialPeri-implantitis; adjunctive to mechanical debridement versus mechanical debridement alonegelperi-implant crevicular fluid1%6 monthsn = 54
Journal of long-term effects of medical implants
Metformin is linked with lower IL-6 in humans (patients with newly diagnosed T2DM).
“significant reductions in TNF-α, IL-6, glycated hemoglobin (HbA1c), and fasting plasma glucose levels were observed in both groups (p < 0.001)”
Humanspatients with newly diagnosed T2DM6 months
Journal of clinical medicine
Metformin decreases IL-6 in PDGFβ-treated orbital fibroblasts from TED patients.
“Metformin treatment restored AMPK phosphorylation, reduced HA accumulation (∼2.3-3.1-fold), and decreased IL-6 and IL-8 production.”
Cellsin PDGFβ-treated orbital fibroblasts from TED patients
Experimental eye research
HOMA-IR
upin humans1no changein humans1downin humans1
3 studies
HOMA-IR
upin humans1no changein humans1downin humans1
Metformin improves HOMA-IR in patients of schizophrenia with metabolic syndrome.
“Metformin showed significant within-group improvements in LDL: HDL ratio and HOMA-IR”
Human trialin patients of schizophrenia with metabolic syndrome1000 mg/dayeight weeks
European archives of psychiatry and clinical neuroscience
Metformin showed no clear effect on HOMA-IR in 21OHD patients (median HOMA-IR, 2.50-2.82).
“Daily 1000 mg metformin therapy for 6 months did not significantly improve IR (median HOMA-IR, 2.50-2.82; p = 0.460)”
Human trialin 21OHD patients1000 mg daily6 months
Journal of diabetes
Metformin decreases HOMA-IR in humans.
“Over the 12-week period, significant time effects were observed for glucose, HOMA-IR, and RBP4 (p < 0.05), as well as for total cholesterol levels (p < 0.01).”
Human trialtwelve-weekfemalesn = 30
Frontiers in endocrinology
Frailty
downin humans1no changein humans1downin mice1
3 studies
Frailty
downin humans1no changein humans1downin mice1
Metformin decreases frailty in humans (frailty index progression, adjusted for covariates including body mass index) (-0.006±0.0026 per year vs. placebo).
“Notably, metformin caused a steady improvement in the frailty index (-0.006±0.0026 per year vs. placebo, p=0.0222)”
Human trialfrailty index progression, adjusted for covariates including body mass indextwo yearsn = 145
A Randomized Clinical Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance
medRxiv : the preprint server for health sciencesPreprint
Metformin showed no clear effect on frailty in non-diabetic people living with HIV (94.1% to 58.8% vs. 88.9% to 77.8%).
“According to the Fried phenotype, the proportion of robust individuals decreased from 94.1% at baseline to 58.8% at week 96 in the metformin group, and from 88.9% to 77.8% in the placebo group, but these changes were not statistically significant (p = 0.355).”
Human trialin non-diabetic people living with HIV96 weeksn = 35
EClinicalMedicine
Metformin decreases frailty in mice.
“Both clinical and performance-based frailty scores were significantly attenuated.”
Animals30 to 53 weeks of agemales
Biogerontology
All 443Fewer
What is metformin linked with?
124Studies link metformin with 124 measures, most often mortality (10 studies), vitamin B12 deficiency (6) and dementia (5).
Mortality
downin humans9no changein humans1HR 0.19–0.83
10 studies
Mortality
downin humans9no changein humans1HR 0.19–0.83
Metformin is associated with mortality in humans (HR 0.60, 95% CI 0.55-0.66).
“All active therapies were associated with lower mortality compared with no observed therapy, including GLP-1RA/SGLT2i (HR 0.71, 95% CI 0.58-0.87), metformin (HR 0.60, 95% CI 0.55-0.66)”
HumansType 2 diabetes after isolated coronary artery bypass grafting; compared with no observed therapyn = 19,237
Initial Diabetes Therapy After Coronary Artery Bypass Grafting and Long-Term Outcomes
Journal of the American Heart Association
Metformin is associated with mortality in humans (Type 2 diabetes and COVID-19; compared with DPP4 inhibitor prescription) (aRR 0.61, 95% CI 0.51–0.73).
“metformin prescription was associated with a lower risk of all‐cause mortality after COVID‐19 (adjusted risk ratio [aRR]: 0.61, 95% CI: 0.51, 0.73).”
HumansType 2 diabetes and COVID-19; compared with DPP4 inhibitor prescription12 monthsn = 53,332
Metformin linked to lower death risk after COVID-19 in diabetes
Diabetes, obesity & metabolism
Metformin is associated with mortality in humans (Cancer patients initiating vascular endothelial growth factor inhibitor therapy) (19.8% vs. 23.0%; HR 0.83, 95% CI 0.79-0.87).
“metformin use was associated with a marked reduction in all-cause mortality and new-onset metastatic disease.”
HumansCancer patients initiating vascular endothelial growth factor inhibitor therapyUp to one year
AHA Scientific Sessions 2026 abstract
Metformin is associated with mortality in humans (Cardiometabolic HFpEF) (HR 0.19, 95% CI 0.05–0.78).
“Statin use (HR = 0.55, 95% CI 0.35-0.86) and metformin (HR = 0.19, 95% CI 0.05-0.78) showed significant protective effects overall.”
HumansCardiometabolic HFpEFn = 1,158
ESC Congress 2026 abstract
Metformin is associated with mortality in humans (type II diabetes).
“Hazard ratios of all-cause mortality were lower among Metformin (HR=0.61, CI=0.31-1.16) and Metformin Combo group (HR=0.96, CI=0.61-1.52) compared to Sulfonylureas (though statistically not significant).”
Humanstype II diabetesn = 120
Preprint
Metformin is linked with a lower risk of mortality in the long-term period after COVID-19 in patients with T2DM (HR 0.40; 95% CI 0.30–0.54, p<0.001).
“A lower risk of death in the long-term period was associated with the use of SGLT2 inhibitors (HR 0.45; 95% CI 0.29–0.70, p<0.001) and metformin (HR 0.40; 95% CI 0.30–0.54, p<0.001).”
Humansin the long-term period after COVID-19 in patients with T2DM
Diabetes Mellitus
Metformin is linked with a lower risk of mortality in humans (HR 0.828, 95% CI 0.799-0.857).
“metformin and thiazolidinedione (TZD) exposure were associated with lower mortality (HR 0.828, 95% CI 0.799-0.857 and HR 0.838, 95% CI 0.793-0.885, respectively)”
Humansafter adjustment for demographics, comorbid conditions, renal function, and hemoglobin A1c; veterans with pulmonary hypertension and diabetes
Pulmonary circulation
Metformin is linked with a lower risk of mortality in humans (patients with type 2 diabetes mellitus without known heart failure) (HR: 0.410, p = 0.019).
“Metformin use was independently associated with lower mortality risk (HR: 0.410, p = 0.019).”
Humanspatients with type 2 diabetes mellitus without known heart failuremedian follow-up of 61 monthsn = 449
Therapeutic advances in endocrinology and metabolism
Metformin is associated with mortality in humans (pooled across mixed human studies in patients with cancer) (HR=0.82, 95% CI: 0.74-0.91).
“Metformin use was associated with lower ACM (HR=0.82, 95% CI: 0.74-0.91, P=0.0001)”
Reviewpooled across mixed human studies in patients with cancer
Pharmacological research
Metformin lowers the risk of mortality in people with type 2 diabetes.
“Metformin use in individuals with T2DM was associated with reduced risk of all-cause mortality, incidence of CVDs, and dementia.”
Reviewin people with type 2 diabetes
Rejuvenation research
Vitamin B12 deficiency
upin humans6OR 1.49–5.33
6 studies
Vitamin B12 deficiency
upin humans6OR 1.49–5.33
Metformin raises the risk of vitamin B12 deficiency in humans (OR 1.49, 95% CI 1.08-1.91).
“participants in the metformin arm had higher odds of B12 deficiency than those receiving placebo (OR= 1.49, 95% CI: 1.08-1.91, p= 0.004).”
Human trialover follow-up
ADA Scientific Sessions 2026 abstract
Metformin is linked with a higher risk of vitamin B12 deficiency in humans (T2DM patients on metformin therapy) (OR 2.34; 95% CI 1.45-3.78).
“Higher daily doses (>1500 mg/day) were independently associated with deficiency (OR 2.34; 95% CI 1.45-3.78).”
HumansT2DM patients on metformin therapy>1500 mg/dayn = 312
International Journal of Drug Delivery Technology
Metformin is linked with a higher risk of vitamin B12 deficiency in adults with type 2 diabetes mellitus (adjusted OR: 2.85; 95% CI: 1.32-6.12).
“multivariate logistic regression analysis identified metformin use for more than five years (adjusted odds ratio (OR): 2.85; 95% confidence interval (CI): 1.32-6.12)”
Humansin adults with type 2 diabetes mellitusmore than five yearsn = 170
Cureus
Metformin is linked with a higher risk of vitamin B12 deficiency in type 2 diabetes mellitus (OR 5.33, 95% CI 2.44-11.65).
“Vitamin B12 deficiency was present in 40.0% of metformin users versus 11.1% of controls, yielding an odds ratio of 5.33 (95% CI: 2.44-11.65)”
Humansin type 2 diabetes mellitus1238.89 ± 586.50 mg/day5.22 ± 3.77 years
To Determine Vitamin B12 Deficiency in Type 2 Diabetes Mellitus Patients on Metformin Therapy
The Journal of the Association of Physicians of India
Metformin is associated with vitamin B12 deficiency in humans (Higher metformin dose in patients with type 2 diabetes mellitus) (Dose AOR 1.002; 95% CI 1.001–1.003).
“metformin dose (AOR: 1.002; 95% CI: 1.001 to 1.003; p < 0.001)”
HumansHigher metformin dose in patients with type 2 diabetes mellitusn = 318
Kathmandu University medical journal (KUMJ)
Metformin is associated with vitamin B12 deficiency in humans (Adults with type 2 diabetes mellitus in Africa).
“Narrative synthesis suggested that older age, longer metformin exposure, and higher metformin doses were the most consistently reported factors associated with vitamin B12 deficiency.”
ReviewAdults with type 2 diabetes mellitus in Africahigher metformin doseslonger metformin exposure
Metabolism open
Dementia
downin humans5HR 0.9
5 studies
Dementia
downin humans5HR 0.9
Metformin lowers the risk of dementia in humans (compared with placebo) (OR 0.40, 95% CI 0.17–0.97).
“randomization to metformin was associated with a 60% (OR 0.40 [95% confidence interval 0.17, 0.97]) and 62% (OR 0.38 [95% confidence interval 0.16, 0.89]) lower odds of dementia compared with placebo and ILS, respectively”
Human trialcompared with placeboaverage intervention duration of 3.2 yearsn = 1,483
Randomized metformin and cognitive outcomes in the Diabetes Prevention Program Outcomes Study
medRxiv : the preprint server for health sciencesPreprint
Metformin lowers the risk of dementia in humans (compared with placebo) (60% lower odds (OR 0.40 [95%CI 0.17, 0.97])).
“randomization to metformin was associated with a 60% (OR 0.40 [95%CI 0.17, 0.97]) and 62% (OR 0.38 [95%CI 0.16, 0.89]) lower odds of dementia compared with placebo”
Human trialcompared with placebo
Randomized metformin and cognitive outcomes in the Diabetes Prevention Program Outcomes Study
medRxiv : the preprint server for health sciencesPreprint
Metformin is associated with dementia in humans (59-62% lower odds vs placebo; 60% lower odds vs intensive lifestyle).
“Randomization to MET was associated with 59-62% and 60% lower odds of dementia compared with PBO and ILS, respectively”
Human trialrandomized allocation to metformin vs placebo or intensive lifestyle, prevalent cognitive impairment assessed 2022-2024n = 1,483
ADA Scientific Sessions 2026 abstract
Metformin is associated with dementia in humans (Metformin initiation compared with sulfonylurea initiation) (HR 0.90, 95% CI 0.82–1.02).
“a lower incidence of dementia (HR: 0.90, 95% CI: [0.82, 1.02]).”
HumansMetformin initiation compared with sulfonylurea initiation
Metformin linked to lower dementia risk in US health records
medRxivPreprint
Metformin is linked with a lower risk of dementia in humans (compared with placebo, Bayesian network meta-analysis) (OR 0.79, 95% CrI 0.77–0.81).
“Metformin [OR = 0.79, 95% CrI (0.77, 0.81)]”
Humanscompared with placebo, Bayesian network meta-analysis
The impact of antidiabetic drugs on dementia risk: a Bayesian network meta-analysis
Frontiers in endocrinology
Metformin lowers the risk of dementia in people with type 2 diabetes.
“Metformin use in individuals with T2DM was associated with reduced risk of all-cause mortality, incidence of CVDs, and dementia.”
Reviewin people with type 2 diabetes
Rejuvenation research
Type 2 diabetes
downin humans3RR 0.65
3 studies
Type 2 diabetes
downin humans3RR 0.65
Metformin lowers the risk of type 2 diabetes in humans (RR = 0.65, 95% CI [0.55, 0.77]).
“The meta-analysis showed that metformin use was associated with a significantly lower risk of progression to T2DM compared with the non-metformin control group (RR = 0.65, 95% CI [0.55, 0.77], P < 0.00001), corresponding to a 35% risk reduction.”
Human trial
Diabetes, metabolic syndrome and obesity : targets and therapy
Metformin lowers the risk of type 2 diabetes in humans (prediabetes) (RR 0.65, 95% CI 0.55–0.77).
“Metformin reduced the risk of progression to T2DM by 35% compared with lifestyle intervention or placebo (RR = 0.65; 95% CI: 0.55-0.77; P < 0.00001)”
Human trialprediabetes
Diabetes, metabolic syndrome and obesity : targets and therapy
Metformin lowers the risk of type 2 diabetes in humans (HR 0.58 (95% CI 0.24–1.32)).
“The hazard ratio for new onset T2DM comparing metformin to placebo was 0.58 (95% CI: 0.24 - 1.32) in the primary analytic model”
Human trialprimary Cox model adjusted for baseline vaccination status and other study drugs; 10 months after randomizationimmediate-release metformin hydrochloride10 monthsn = 1,136
Can 14 Days of Metformin Prevent Post-COVID Diabetes?
ADA Scientific Sessions 2026 abstract
Metformin lowers the risk of type 2 diabetes in selected high-risk individuals with prediabetes.
“Metformin remains the glucose-lowering agent with the most established long-term evidence for diabetes prevention in selected high-risk individuals with prediabetes”
Reviewin selected high-risk individuals with prediabetes
Current medical research and opinion
Glaucoma
no changein humans2downin humans2OR 0.96
3 studies
Glaucoma
no changein humans2downin humans2OR 0.96
Metformin is associated with glaucoma in humans (newly diagnosed type 2 diabetes mellitus) (adjusted HR 1.076, 95% CI 0.995-1.163, p=0.067).
“metformin monotherapy (N=100,387) showed a non-significant trend toward higher glaucoma diagnosis rates compared to matched controls (HR 1.106, 95% CI 1.014-1.207, p=0.023; adjusted HR 1.076, 95% CI 0.995-1.163, p=0.067).”
Humansnewly diagnosed type 2 diabetes mellitusn = 100,387
Clinical ophthalmology (Auckland, N.Z.)
Metformin is linked with a lower risk of glaucoma in humans (individuals of European ancestry with diabetes) (HR 0.81, 95% CI 0.67-0.97).
“Metformin use was associated with a 19% lower glaucoma risk (hazard ratio, 0.81; 95% confidence interval [CI], 0.67-0.97; P = 0.019) in individuals of European ancestry”
Humansindividuals of European ancestry with diabetes12.1 ± 2.8 yearsn = 24,206
Ophthalmology science
Metformin lowers the risk of glaucoma in humans (time-to-event analysis, adjusted models) (aHR = 0.88; 95% CI, 0.80-0.96).
“persisted in adjusted models (aHR = 0.88; 95% CI, 0.80-0.96; I2 = 0.01%; moderate certainty).”
Reviewtime-to-event analysis, adjusted models
Metformin Use and Risk of Glaucoma: A Systematic Review and Meta-Analysis
American journal of ophthalmology
Metformin is associated with glaucoma in humans (crude binary analysis) (OR = 0.96; 95% CI, 0.87-1.06).
“The pooled crude OR showed no association between metformin use and glaucoma risk (OR = 0.96; 95% CI, 0.87-1.06; I2 = 79.14%; low certainty).”
Reviewcrude binary analysis
Metformin Use and Risk of Glaucoma: A Systematic Review and Meta-Analysis
American journal of ophthalmology
Cognitive function
upin humans3
3 studies
Cognitive function
upin humans3
Metformin is associated with cognitive function in humans (Community-dwelling older adults with type 2 diabetes; metformin users versus non-users) (MMSE change 0.0 versus −0.7; p<0.001; unlikely to be clinically meaningful in the short term).
“At 2 years, metformin users maintained stable MMSE scores, while non-users showed a slight decrease (0.0 vs −0.7; p<0.001)”
HumansCommunity-dwelling older adults with type 2 diabetes; metformin users versus non-users2 years46.1% womensn = 412
BMJ open
Metformin is associated with cognitive function in humans (type 2 diabetes) (47.5 vs. 39.5).
“Metformin is associated with better cognition in older T2DM adults.”
Humanstype 2 diabetesn = 587
Diabetes, obesity & metabolism
Metformin is associated with cognitive function in humans.
“Metformin-treated patients had higher Mini-ACE scores and elevated serum BDNF and NGF.”
Humans
The Egyptian Journal of Internal Medicine
Survival
upin humans1upin zebrafish1
2 studies
Survival
upin humans1upin zebrafish1
Metformin is associated with survival in zebrafish (co-administered with high glucose (150 mM)).
“Metformin was associated with improved survival, cardiac phenotypes, and locomotor outcomes, together with partial molecular restoration.”
Animalsco-administered with high glucose (150 mM)0.75, 3.0, or 6.0 mM
Pharmaceuticals (Basel, Switzerland)
Metformin is associated with survival in humans (selected patients with cirrhosis).
“metformin use is associated with improved survival in selected patients with cirrhosis”
Reviewselected patients with cirrhosis
Biochemical pharmacology
Gut microbial composition
mixedin mice1mixedin reviews1
2 studies
Gut microbial composition
mixedin mice1mixedin reviews1
Metformin is associated with gut microbial composition.
“Metformin is consistently associated with reshaping of gut microbial composition, enriching Akkermansia muciniphila and short-chain fatty acid (SCFA)- producing taxa”
Reviewgut
Gut Microbiota and Antidiabetic Drugs: A bidirectional relationship
Frontiers in pharmacology
Metformin is associated with gut microbial composition in mice (LPS-induced injury).
“Metagenomics showed metformin-associated remodeling of gut microbial composition and predicted gene-content functional potential.”
AnimalsLPS-induced injurycolonic contents400 mg/kg7 days before intranasal LPS challengemales
Pharmaceuticals (Basel, Switzerland)
Cardiovascular disease
downin humans2OR 0.69
2 studies
Cardiovascular disease
downin humans2OR 0.69
Metformin lowers the risk of cardiovascular disease in humans (versus placebo in type 2 diabetes) (OR 0.69, 95% CI 0.53-0.89).
“metformin (OR 0.69, 95% CI 0.53-0.89), SGLT2i (0.82, 0.75-0.90), GLP1RA (0.87, 0.83-0.92) and tirzepatide (0.82, 0.72-0.93) were associated with a significant reduction of MACE versus placebo”
Human trialversus placebo in type 2 diabetesat least 40 weeks
Diabetes, obesity & metabolism
Metformin lowers the risk of cardiovascular disease in people with type 2 diabetes.
“Metformin use in individuals with T2DM was associated with reduced risk of all-cause mortality, incidence of CVDs, and dementia.”
Reviewin people with type 2 diabetes
Rejuvenation research
Lactic acidosis
upin humans2HR 3.14
2 studies
Lactic acidosis
upin humans2HR 3.14
Metformin is linked with a higher risk of lactic acidosis in very elderly patients with CKD and type 2 diabetes (HR 3.14 (95% CI 1.75-5.65)).
“and lactic acidosis (HR 3.14; 95% CI 1.75-5.65)”
Humansin very elderly patients with CKD and type 2 diabetes
Medicina (Kaunas, Lithuania)
Metformin raises the risk of lactic acidosis in humans (renal-impaired or elderly patients).
“contrasted by long-term risks like lactic acidosis and neurodegeneration in renal-impaired or elderly patients.”
Reviewrenal-impaired or elderly patientslong-term
Problemy endokrinologii
Low birth weight
upin humans1
1 study
Low birth weight
upin humans1
Metformin raises the risk of low birth weight in humans among women carrying a female foetus (8.3% vs. 1.9%).
“Among women carrying a female foetus, metformin usage was associated with reduced maternal weight gain (0.5 vs. 2.3 kg, p < 0.001), lowered fasting glucose at 38 weeks (4.47 mmol/L vs. 4.63 mmol/L, p = 0.046) and a higher rate of low birth weight infants (8.3% vs. 1.9%, p = 0.032) compared to placebo use”
Human trialamong women carrying a female foetusn = 236
BMC medicine
Metformin raises the risk of low birth weight in female pregnancies complicated by GDM (8.3% vs. 1.9%, p = 0.032).
“Metformin-exposed females had higher rates of birth weight < 2500 g compared to those exposed to placebo (8.3% vs. 1.9%, p = 0.032)”
Human trialin female pregnancies complicated by GDMfemales
BMC medicine
Testosterone
downin humans1
1 study
Testosterone
downin humans1
Metformin is associated with testosterone in humans (PCOS; before-and-after comparison without an untreated comparator) (0.81 ± 0.07 to 0.73 ± 0.08 ng/mL).
“Testosterone declined significantly from 0.81 ± 0.07 to 0.73 ± 0.08 ng/mL (p < 0.001)”
Human trialPCOS; before-and-after comparison without an untreated comparatormaximum of 2.55–3.0 g/day6 monthsfemalesn = 120
Pathophysiology : the official journal of the International Society for Pathophysiology
Luteinizing hormone
downin humans1
1 study
Luteinizing hormone
downin humans1
Metformin is associated with luteinizing hormone in humans (PCOS; before-and-after comparison without an untreated comparator) (11.28 ± 1.34 to 8.55 ± 1.11 IU/L).
“In women with PCOS, LH decreased significantly from 11.28 ± 1.34 to 8.55 ± 1.11 IU/L (p < 0.001)”
Human trialPCOS; before-and-after comparison without an untreated comparatormaximum of 2.55–3.0 g/day6 monthsfemalesn = 120
Pathophysiology : the official journal of the International Society for Pathophysiology
Total prolactin
downin humans1
1 study
Total prolactin
downin humans1
Metformin is associated with total prolactin in humans (Prediabetes without PCOS; before-and-after comparison without an untreated comparator) (45.51 ± 5.05 to 37.87 ± 4.63 ng/mL).
“whereas they decreased significantly in controls (45.51 ± 5.05 to 37.87 ± 4.63 ng/mL; p < 0.001)”
Human trialPrediabetes without PCOS; before-and-after comparison without an untreated comparatormaximum of 2.55–3.0 g/day6 monthsfemalesn = 120
Pathophysiology : the official journal of the International Society for Pathophysiology
HOMA1-IR
downin humans1
1 study
HOMA1-IR
downin humans1
Metformin is associated with HOMA1-IR in humans (PCOS; before-and-after comparison without an untreated comparator) (3.27 ± 0.36 to 2.83 ± 0.39).
“The Homeostatic Model Assessment for Insulin Resistance (HOMA1-IR) also decreased significantly, from 3.27 ± 0.36 to 2.83 ± 0.39 (p < 0.001)”
Human trialPCOS; before-and-after comparison without an untreated comparatormaximum of 2.55–3.0 g/day6 monthsfemalesn = 120
Pathophysiology : the official journal of the International Society for Pathophysiology
All 124Fewer
Has metformin been tested in people?
140 of 1,170 about agingYes: 220 trials and 503 observational studies in people have been published, and 1,152 trials are registered.
About aging
Pilot Study on Evaluating the Geroprotective Effect of Metformin
Phase 2Recruiting
Combination Gerotherapeutic Interventions for Healthspan Improvement
Phase 3Completed
ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging
Phase 2Completed
Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
Early phase 1Enrolling by invitation
Metformin for Preventing Frailty in High-risk Older Adults
Phase 2Completed
Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors
Phase 3Completed
All 40Fewer
Latest change Prediabetes: Human trials → Phase 3Nov 16, 2026
Approved
Mar 3, 1995Discontinued
Oct 13, 2000Discontinued
Sep 11, 2003Discontinued
Apr 27, 2004Discontinued
Jun 3, 2005DiscontinuedDiabetes Mellitus, Type 2
Aug 29, 2019Discontinued
Repurposing
Phase 4Results posted52 trials
Phase 4Completed9 trials
Phase 4Completed6 trials
Phase 4Results posted106 trials
Phase 4Results posted6 trials
Phase 4Status unknown1 trial
40 of 300Fewer
Every condition in trials
Prostatic neoplasm
Phase 4Status unknown22 trials
Motor Activity
Phase 4Results posted8 trials
Lipoatrophic diabetes mellitus
Phase 4Completed6 trials
Fasting
Phase 4Completed3 trials
Melanosis
Phase 4Status unknown2 trials
Other Conditions That May Be A Focus of Clinical Attention
Phase 4Results posted2 trials
40 of 74Fewer
Readouts due
- Nov 30, 2026
Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects
Phase 1Not yet recruiting
- Dec 2026
- Dec 1, 2026
- Dec 5, 2026
Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants
Phase 1Active, not recruiting
- Dec 30, 2026
Metabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS
Phase 4Active, not recruiting
- Dec 30, 2026
Fish Oil, Metformin and Heart Health in PCOS
Phase 1Recruiting
All 25Fewer
Stopped
NCT02409238TerminatedType 2 diabetes
1. Limits of grant funding reached 2. A/Prof Ng Tze Pin (P.I. \& holder of NMRC Grant (CIRG12may033) funding this study) retired in Aug 2022. 3. Resignations of staff and collaborators especially over the 1st 2 years of the COVID-19 pandemic
NCT03118713TerminatedType 2 diabetes
Business decision due to enrollment challenges
NCT03258723TerminatedDiabetes mellitus
COVID-19 led to changes in study design and an early end to data collection.
NCT04416269TerminatedDiabetes mellitus
The study was suspended and during this time recruitment and study activities were halted. The study was ultimately terminated in April 2026 without having re-opened for recruitment additional participants.
NCT01799057TerminatedInsulin resistance
The trial has been terminated due to difficulties with recruitment.
NCT03380091TerminatedInsulin resistance
Recruitment challenges
40 of 43Fewer
Who is developing metformin?
3 companies: AstraZeneca, Nabiqasim Industries (Pvt) and Johnson & Johnson Private.
Trial sponsors
Company37 trialsPhase 44,231 people
Company32 trialsPhase 410,846 people
Company23 trialsPhase 46,019 people
Company21 trialsPhase 45,290 people
Janssen Research & Development
Company19 trialsPhase 41,989 people
Company16 trialsPhase 411,206 people
Company13 trialsPhase 44,096 people
Company9 trialsPhase 4944 people
Funding
207 grants since 2016National Institute on Aging$72.9MNational Institute of Diabetes and Digestive and Kidney Diseases$20.8MNational Heart, Lung, and Blood Institute$20.9M
Lifestyle Intervention plus Metformin to Treat Frailty in Older Veterans with Obesity
US Department of Veterans AffairsMichael E. DeBakey VA Medical Center2020–2026
Impact of in utero metformin exposure on offspring growth and metabolic outcomes
National Institute of Child Health and Human DevelopmentEast Carolina University$685K2026–2031
National Heart, Lung, and Blood InstituteBaylor College of Medicine$678K2024–2028
National Institute on AgingMayo Clinic Rochester$1.7M2026–2031
Molecular effects of metformin, PKR and TBI on C9orf72 ALS/FTD
National Institute of Neurological Disorders and StrokeUniversity of Florida$702K2016–2027
Trial Readiness for Metformin in Aortic Valve Stenosis
National Heart, Lung, and Blood InstituteUniv of Massachusetts Med Sch Worcester$745K2026–2029
National Institute on AgingDuke University$243K2025–2030
Metformin to prevent chemotherapy-induced neurotoxicity among children with leukemia
National Cancer InstituteRutgers Biomedical and Health Sciences$601K2026–2031
Re-Purposing of Metformin as a Countermeasure for Radiation-Combined Injuries
National Institute of Allergy and Infectious DiseasesUniversity of Pittsburgh at Pittsburgh$159K2025–2027
Targeting Biology of Aging Mechanisms Underlying Alzheimer's Disease Risk with Metformin
National Institute on AgingCedars-Sinai Medical Center$712K2024–2029